The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aducanumab (1) binds to 3-7 amino acids of Aβ, targeting soluble oligomers and insoluble fibrils.418,419”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [418]
In the citing paper
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [56]
In the citing paper
“Additionally, amyloid was cleared from the six cortical regions of interest, namely the frontal, parietal, lateral temporal, sensorimotor, anterior, and posterior cingulate areas [43].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Studies have shown that amyloid deposition was reduced in all treatment groups at 26 weeks and further reduced by the end of the first year.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Anti-Aβ immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [173]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 601–700 of 1,043
Han, Y., Chen, R., Lin, Q., Liu, Y., Ge, W., Cao, H., & Li, J. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16855 · Cited by 67
Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation
Braun, G. A., Dear, A. J., Sanagavarapu, K., Zetterberg, H., & Linse, S. S. (2022) · Chemical Science · doi:10.1039/d1sc02990h · Cited by 76
Piazza, F., Caminiti, S. P., Zedde, M., Presotto, L., DiFrancesco, J. C., Pascarella, R., Giossi, A., Sessa, M., Poli, L., Basso, G., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200892 · Cited by 69
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 72
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Barrera-Ocampo, A., & Lopera, F. (2016) · Colombia Medica · doi:10.25100/cm.v47i4.2640 · Cited by 63
Kälin, A. M., Park, M. T. M., Chakravarty, M. M., Lerch, J. P., Michels, L., Schroeder, C., Broicher, S. D., Kollias, S., Nitsch, R. M., Gietl, A. F., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00038 · Cited by 69
“Following the concept of the amyloid-hypothesis, Alzheimer’s disease (AD) treatment methods that are currently under investigation may be most efficacious in preclinical or early disease stages (Golde et al., 2011; Sperling et al., 2011; Sevigny et al., 2016), referred to as mild cognitive impairment (MCI).”
BackgroundInfluentialSelf-citationImpact of aging immune system on neurodegeneration and potential immunotherapies
Liang, Z., Zhao, Y., Ruan, L., Zhu, L., Jin, K., Zhuge, Q., Su, D., & Zhao, Y. L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.07.006 · Cited by 67
Zhao, Y., Zhao, R., Wu, J., Wang, Q., Pang, K., Shi, Q., Gao, Q., Hu, Y., Dong, X., Zhang, J., et al. (2018) · BioFactors · doi:10.1002/biof.1411 · Cited by 55
“Ab oligomers, a death-promoting peptide, play a central role in inducing synaptic toxicity associated with synaptic dysfunction and neuronal death both in vivo and in vitro [6,8,35,36].”
Li, S., Jin, M., Liu, L., Dang, Y., Ostaszewski, B. L., & Selkoe, D. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0626-x · Cited by 63
“More recent trials that began treating at early or very early symptomatic stages of AD and used substantial doses of N-terminally-directed antibodies appear to clear amyloid plaques and lead to some apparent slowing of cognitive decline [61, 63].”
Brain delivery of biologics using a cross‐species reactive transferrin receptor 1 VNAR shuttle
Sehlin, D., Stocki, P., Gustavsson, T., Hultqvist, G., Walsh, F. S., Rutkowski, J. L., & Syvänen, S. (2020) · The FASEB Journal · doi:10.1096/fj.202000610rr · Cited by 65
Martínková, J., Quevenco, F., Karcher, H., Ferrari, A., Sandset, E. C., Szoeke, C. E. I., Hort, J., Schmidt, R., Chadha, A. S., & Ferretti, M. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24124 · Cited by 68
Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA.
Pizzo, M. E., Plowey, E. D., Khoury, N., Kwan, W., Abettan, J., DeVos, S. L., Discenza, C. B., Earr, T., Joy, D., Lye-Barthel, M., et al. (2025) · Science · doi:10.1126/science.ads3204 · Cited by 63
Self-citationWalters, S., Contreras, A. G., Eissman, J. M., Mukherjee, S., Lee, M. L., Choi, S.-E., Scollard, P., Trittschuh, E. H., Mez, J. B., Bush, W. S., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.2169 · Cited by 60
Review on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 72
Scuteri, D., Morrone, L. A., Rombolà, L., Avato, P., Bilia, A. R., Corasaniti, M. T., Sakurada, S., Sakurada, T., & Bagetta, G. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/9416305 · Cited by 74
“Therefore, the studies on Aducanumab support the amyloid hypothesis and demonstrate that the use of Aducanumab could be an interesting disease-modifying approach for AD treatment in the still ongoing long-term extension (LTE) phase of the PRIME and phase 3 studies [12].”
BackgroundMethodMethods of probing the interactions between small molecules and disordered proteins
Heller, G. T., Aprile, F. A., & Vendruscolo, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2563-4 · Cited by 64
“Since the first production of conformationally distinct antibodies able to uniquely target fibrillar and oligomeric species of various amyloidogenic proteins [105], many other amyloid-specific antibodies have been generated by means of direct immunization or using hybridoma technology [101], phage”
BackgroundActive poly‐GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model
Zhou, Q., Mareljic, N., Michaelsen, M., Parhizkar, S., Heindl, S., Nuscher, B., Farny, D., Czuppa, M., Schludi, C., Graf, A., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910919 · Cited by 64
Ruano-Salguero, J. S., & Lee, K. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-60438-z · Cited by 64
Direct measurement of lipid membrane disruption connects kinetics and toxicity of Aβ42 aggregation
Flagmeier, P., De, S., Michaels, T. C. T., Yang, X., Dear, A. J., Emanuelsson, C. S., Vendruscolo, M., Linse, S. S., Klenerman, D., Knowles, T. P. J., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0471-z · Cited by 67
Panza, F., Lozupone, M., Dibello, V., Greco, A., Daniele, A., Seripa, D., Logroscino, G., & Imbimbo, B. P. (2019) · Immunotherapy · doi:10.2217/imt-2018-0119 · Cited by 60
Mallucci, G. R., Klenerman, D., & Rubinsztein, D. C. (2020) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-040320-120625 · Cited by 62
Amyloid-β: A double agent in Alzheimer's disease?
Yu, H., & Wu, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111575 · Cited by 62
He, S., Xu, Z., & Han, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00803-6 · Cited by 62
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
Nan, K., Han, Y., Fang, Q., Huang, C., Yu, L., Ge, W., Xiang, F., Tao, Y.-X., Cao, H., & Li, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.027 · Cited by 62
Koenig, L. N., Day, G. S., Salter, A. R., Keefe, S., Marple, L. M., Long, J. M., LaMontagne, P., Massoumzadeh, P., Snider, B. J., Kanthamneni, M., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102248 · Cited by 70
Aducanumab: The first targeted Alzheimer's therapy
Yang, P., & Sun, F. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01061 · Cited by 67
“Aducanumab is the first therapy to prove that removing Aβ leads to better clinical outcomes (7).”
Backgroundα‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives
Alzghool, O. M., van Dongen, G. A. M. S., van de Giessen, E., Schoonmade, L. J., & Beaino, W. (2022) · Movement Disorders · doi:10.1002/mds.28984 · Cited by 67
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
Pardridge, W. M. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1227816 · Cited by 67
The Role of Glial Cells in Synaptic Dysfunction: Insights into Alzheimer's Disease Mechanisms
Yu, Y., Chen, R., Mao, K., Deng, M., & Li, Z. (2023) · Aging and Disease · doi:10.14336/ad.2023.0718 · Cited by 66
“The recovery of cognitive function has been demonstrated by altering the excitatory synaptic transmission dysfunction in the hippocampus using antibodies [18] and inhibitors [19], suggesting that targeting synaptic dysfunction may be a new therapy for AD.”
BackgroundIndole-Based Compounds in the Development of Anti-Neurodegenerative Agents
Barresi, E., Baglini, E., Poggetti, V., Castagnoli, J., Giorgini, D., Salerno, S., Taliani, S., & Settimo, F. D. (2024) · Molecules · doi:10.3390/molecules29092127 · Cited by 63
Söderberg, L., Johannesson, M., Gkanatsiou, E., Nygren, P., Fritz, N., Zachrisson, O., Rachalski, A., Svensson, A.-S., Button, E. B., Dentoni, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61691-2 · Cited by 71
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions
Rafii, M. S., & Aisen, P. S. S. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01123-5 · Cited by 73
“The phase I PRIME study of aducanumab has demonstrated cognitive benefits, especially in participants who achieved significant Aβ clearance, marking the first such findings 19 .”
InfluentialNovel targets in Alzheimer’s disease: A special focus on microglia
Balducci, C., & Forloni, G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.017 · Cited by 66
Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease
Wang, Z., Gao, G., Duan, C., & Yang, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108843 · Cited by 60
Organoplatinum-Substituted Polyoxometalate Inhibits β-amyloid Aggregation for Alzheimer's Therapy.
Zhao, J., Li, K., Wan, K.-W., Sun, T.-D., Zheng, N., Zhu, F., Ma, J., Jiao, J., Li, T.-C., Ni, J., et al. (2019) · Angewandte Chemie · doi:10.1002/anie.201910521 · Cited by 48
Morrone, C. D., Bazzigaluppi, P., Beckett, T. L., Hill, M. E., Koletar, M. M., Stefanovic, B., & McLaurin, J. (2019) · Brain · doi:10.1093/brain/awz371 · Cited by 68
“Similar to our study, immunotherapy trials for Alzheimer’s disease demonstrated brain plaque clearance (Sevigny et al., 2016; Ostrowitzki et al., 2017; Nicoll et al., 2019) or inhibition of further accumulation (Salloway et al., 2018).”
ResultAmyloid Load: A More Sensitive Biomarker for Amyloid Imaging
Whittington, A., & Gunn, R. N. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210518 · Cited by 60
“This capacity will have a dramatic effect on the financial cost and disruption to patients in interventional studies and clinical trials and comes at an important time as it has recently been reported that aducanumab reduces Ab in AD (20).”
BackgroundChen, M., Chen, Y., Huo, Q., Wang, L., Tan, S., Misrani, A., Jiang, J., Chen, J., Chen, S., Zhang, J., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00434-7 · Cited by 68
Du, C., Wang, L., Guan, Q., Yang, H., Chen, T., Liu, Y., Li, Q., Lyu, W., Lü, X., Chen, Y., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00944 · Cited by 65
Self-citationLessons Learned from Approval of Aducanumab for Alzheimer's Disease
Heidebrink, J. L., & Paulson, H. L. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-051022-043645 · Cited by 70
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 59
“In December 2014, Biogen announced that aducanumab would move into Phase III based on these interim data of the PRIME study suggesting target engagement and a cognitive benefit [96].”
BackgroundThe Role of Mitochondrial Dysfunction in the Progression of Alzheimer’s Disease
Desler, C., Lillenes, M. S., Tønjum, T., & Rasmussen, L. J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170616110111 · Cited by 61
Ritchie, C. W., Russ, T. C., Banerjee, S., Barber, B., Boaden, A., Fox, N. C., Holmes, C., Isaacs, J. D., Leroi, I., Lovestone, S., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0312-4 · Cited by 62
“However, almost 100 treatments are currently being investigated, often targeting individuals earlier in the disease process [4], and very promising phase II work has been published [5].”
BackgroundTonda‐Turo, C., Origlia, N., Mattu, C., Accorroni, A., & Chiono, V. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180221125759 · Cited by 65
Dekker, A. D., Sacco, S., Carfì, A., Benejam, B., Vermeiren, Y., Beugelsdijk, G., Schippers, M., Hassefras, L., Eleveld, J., Grefelman, S., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170920 · Cited by 65
The Future of Anti-Amyloid Trials
Aisen, P. S., Cummings, J., Doody, R., Kramer, L., Salloway, S., Selkoe, D. J., Sims, J., Sperling, R. A., & Vellas, B. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2020.24 · Cited by 59
“The Task Force discussed five anti-amyloid monoclonal ant ibody therapies current ly in clinical development: aducanumab (7), BAN2401 (6), gantenerumab (8), solanezumab (9–13) , and donanemab.”
BackgroundSelf-citationSenescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis
Walton, C. C., Begelman, D., Nguyen, W., & Andersen, J. K. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00129 · Cited by 62
Ghotbi, G., Mahdavi, M. R., Najafi, Z., Moghadam, F. H., Hamzeh‐Mivehroud, M., Davaran, S., & Dastmalchi, S. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104186 · Cited by 66
Wang, H., Xu, X., Pan, Y., Yan, Y., Hu, X., Chen, R., Ravoo, B. J., Guo, D., & Zhang, T. (2020) · Advanced Materials · doi:10.1002/adma.202006483 · Cited by 65
Merck ends trial of potential Alzheimer’s drug verubecestat
Hawkes, N. (2017) · BMJ · doi:10.1136/bmj.j845 · Cited by 59
Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab
Sveikata, L., Charidimou, A., & Viswanathan, A. (2021) · Stroke · doi:10.1161/strokeaha.121.036873 · Cited by 63
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
Lumsden, A. L., Rogers, J. T., Majd, S., Newman, M., Sutherland, G. T., Verdile, G., & Lardelli, M. T. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00533 · Cited by 63
“Indeed, this might explain why one candidate anti-Aβ therapy has been seen to have ameliorative effects (even if somewhat minor) on Alzheimer’s disease progression in a phase 1b clinical trial (Sevigny et al., 2016, 2017).”
BackgroundTherapeutic Strategies to Target Calcium Dysregulation in Alzheimer’s Disease
Calvo-Rodríguez, M., Kharitonova, E. K., & Bacskai, B. J. (2020) · Cells · doi:10.3390/cells9112513 · Cited by 68
“Although these therapies have shown some success in clearing Aβ plaques from the AD brain, they have failed to relieve the cognitive decline of AD patients in clinical trials [24], with the exception of aducanumab, which demonstrated both clearance of plaques and modest gains in cognitive function [25].”
BackgroundAlzheimer disease neuropathology in a patient previously treated with aducanumab
Plowey, E. D., Bussiere, T., Rajagovindan, R., Sebalusky, J., Hamann, S., von Hehn, C., Castrillo-Viguera, C., Sandrock, A., Budd Haeberlein, S., van Dyck, C. H., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02433-4 · Cited by 56
Self-citationTranslational molecular imaging and drug development in Parkinson’s disease
Haider, A., Elghazawy, N. H., Dawoud, A., Gebhard, C., Wichmann, T., Sippl, W., Hoener, M. C., Arenas, E., & Liang, S. H. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00600-z · Cited by 64
“Of note, drug development efforts in Alzheimer’s disease revealed that immunotherapies directed at aggregated forms of Aβ, with the particular aim not to target monomeric Aβ, proved to be highly promising [109, 110].”
Promoting Alzheimer’s disease research and therapy with stem cell technology
Cao, Z., Kong, F., Ding, J., Chen, C., He, F., & Deng, W. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03737-w · Cited by 67
“It is worth mentioning that humanized AD mouse models have also played a key role in evaluating the amyloid hypothesis [208].”
BackgroundAn intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice
Cheng, Y.-S., Chen, Z.-T., Liao, T., Lin, C. W., Shen, H. C.-H., Wang, Y., Chang, C., Liu, R., Chen, R. P. ‐., & Tu, P. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606666 · Cited by 63
“The preliminary success of ART with aducanumab immunotherapy in decreasing cognitive decline further strengthens this hypothesis (Moreth et al , 2013; Lannfelt et al , 2014; Ratner, 2015; Underwood, 2015; Selkoe & Hardy, 2016; Sevigny et al , 2016).”
Fiorito, J., Vendôme, J., Saeed, F., Staniszewski, A., Zhang, H., Yan, S., Deng, S., Arancio, O., & Landry, D. W. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00979 · Cited by 60
HIV-1 counteracts an innate restriction by amyloid precursor protein resulting in neurodegeneration
Chai, Q., Jovasevic, V., Malikov, V., Sabo, Y., Morham, S., Walsh, D., & Naghavi, M. H. (2017) · Nature Communications · doi:10.1038/s41467-017-01795-8 · Cited by 59
Protein aggregation in cell biology: An aggregomics perspective of health and disease
Cox, D., Raeburn, C., Sui, X., & Hatters, D. M. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.05.003 · Cited by 65
Merchant, K., Cedarbaum, J. M., Brundin, P., Dave, K. D., Eberling, J. L., Espay, A. J., Hutten, S. J., Javidnia, M., Luthman, J., Maetzler, W., et al. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181471 · Cited by 63
Hark, T. J., Rao, N. R., Castillon, C., Basta, T., Smukowski, S. N., Bao, H., Upadhyay, A., Bomba-Warczak, E. K., Nomura, T., O'Toole, E. T., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.11.007 · Cited by 63
True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation
Chen, K. T., Toueg, T. N., Koran, M. E. I., Davidzon, G., Zeineh, M., Holley, D., Gandhi, H., Halbert, K., Boumis, A., Kennedy, G., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05151-9 · Cited by 64
“To leverage its exquisite sensitivity [4–6], more frequent PET scans can be used to understand the pathogenesis of the brain proteinopathies involved in dementia [7], to identify at-risk individuals, and to indicate the optimal time point for early intervention in potential anti-amyloid therapies [8].”
BackgroundUnderstanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease
Xiong, Y., & Lim, C. (2021) · Brain Sciences · doi:10.3390/brainsci11091211 · Cited by 62
“Although aducanumab (Aduhelm) against Aβ [25] was recently approved by the US FDA, it has many limitations due to brain swelling and tiny brain bleeds, no effect on the middle and late phases of AD, and too high a cost to be effective.”
BackgroundTurning the tide on Alzheimer’s disease: modulation of γ-secretase
Luo, J. E., & Li, Y.-M. (2022) · Cell & Bioscience · doi:10.1186/s13578-021-00738-7 · Cited by 59
“Aducanumab, a human monoclonal antibody which targets aggregated amyloid-beta (Aβ), reduced amyloid plaques in the brain, and is expected to delay cognitive decline [2, 3].”
BackgroundJack, C. R., Therneau, T. M., Lundt, E. S., Wiste, H. J., Mielke, M. M., Knopman, D. S., Graff-Radford, J., Lowe, V. J., Vemuri, P., Schwarz, C. G., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac017 · Cited by 56
“target fibrillar forms of β-amyloid can effectively decrease amyloid load.(84,85) While our data are observational and therefore cannot prove that removing amyloid would reduce incidence rates or absolute risk of dementia, the results show that those with higher amyloid progress to dementia at faster rates and have si…”
Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.022 · Cited by 66
“32 Another monoclonal antibody, lecanemab, targeting toxic A b proto fi brils, has shown promise in a phase II clinical trial.”
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 66
Jung, M., Lee, S., Park, S., Hong, J., Kim, C., Cho, I., Sohn, H. S., Kim, K., Park, I. W., Yoon, S., et al. (2023) · Advanced Materials · doi:10.1002/adma.202207719 · Cited by 54
Dunham, S. J. B., McNair, K., Adams, E. D., Avelar‐Barragan, J., Forner, S., Mapstone, M. E., & Whiteson, K. (2022) · mBio · doi:10.1128/mbio.01794-22 · Cited by 62
Schilling, L. P., Balthazar, M. L. F., Radanovic, M., Forlenza, O. V., Silagi, M. L., Smid, J., Barbosa, B. J. A. P., Frota, N. A. F., de Souza, L. C., Vale, F. A. C., et al. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-s102pt · Cited by 135
Metal–Organic Frameworks as Sensors for Human Amyloid Diseases
Leite, J. P., Figueira, F., Mendes, R. F., Paz, F. A. A., & Gales, L. (2023) · ACS Sensors · doi:10.1021/acssensors.2c02741 · Cited by 59
Liu, Z., Deng, Q., Qin, G., Yang, J., Zhang, H., Ren, J., & Qu, X. (2023) · Chem · doi:10.1016/j.chempr.2023.06.003 · Cited by 60
Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 63
Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer’s Disease Therapeutics
Dias, D., & Socodato, R. (2025) · Biomedicines · doi:10.3390/biomedicines13020279 · Cited by 70
“In this case, aducanumab binds to amyloid-beta plaques and prompts the body’s immune cells (microglia) to attack and clear them [54].”
Castro, P., Zaman, S., & Holland, A. (2017) · Journal of Neurology · doi:10.1007/s00415-016-8308-8 · Cited by 55
“2 Hypothetical model for development of dementia in people with Down’s syndrome [81] J Neurol”
BackgroundReview: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease
Ameen‐Ali, K. E., Wharton, S. B., Simpson, J. E., Heath, P. R., Sharp, P., & Berwick, J. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12440 · Cited by 60
Nanodisc-Forming Scaffold Protein Promoted Retardation of Amyloid-Beta Aggregation
Sahoo, B. R., Genjo, T., Cox, S. J., Stoddard, A. K., Anantharamaiah, G. M., Fierke, C. A., & Ramamoorthy, A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.08.018 · Cited by 59
“Different molecular targets such as small molecule compounds [29,30], peptides [31–33], antibodies [34,35] etc.”
BackgroundCai, X., Zhang, K., Xie, X., Zhu, X., Feng, J., Jin, Z., Zhang, H., Tian, M., & Chen, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119678 · Cited by 60
Synergistic Inhibitory Effect of GQDs–Tramiprosate Covalent Binding on Amyloid Aggregation
Liu, Y., Xu, L.-P., Wang, Q., Yang, B., & Zhang, X. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00439 · Cited by 58
Diagnosis and Treatment of Alzheimer’s Disease:
Bomasang-Layno, E., & Bronsther, R. (2021) · Delaware Journal of Public Health · doi:10.32481/djph.2021.09.009 · Cited by 76
The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence
Silva‐Spínola, A., Baldeiras, I., Arrais, J. P., & Santana, I. J. (2022) · Biomedicines · doi:10.3390/biomedicines10020315 · Cited by 66
“Even with the promising results of aducanumab [97] and its conditional approval by the United States Food and Drug Administration (FDA) as a treatment for AD in June 2021, skepticism remains among clinicians.”
BackgroundNeuroimaging in Dementia: More than Typical Alzheimer Disease
Haller, S., Jäger, H. R., Vernooij, M. W., & Barkhof, F. (2023) · Radiology · doi:10.1148/radiol.230173 · Cited by 63
Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 62
Technological advancements in antibody-based therapeutics for treatment of diseases
Lu, R., Chiang, H.-L., Yuan, J. P., Wang, H.-H., Chen, C.-Y., Panda, S. S., Liang, K.-H., Peng, H., Ko, S.-H., Hsu, H.-J., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01190-2 · Cited by 68
Banerjee, S., Hashemi, M., Lv, Z., Maity, S., Rochet, J., & Lyubchenko, Y. L. (2017) · Scientific Reports · doi:10.1038/srep45592 · Cited by 58
The companion dog as a unique translational model for aging
Mazzatenta, A., Carluccio, A., Robbe, D., Giulio, C. D., & Cellerino, A. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.08.024 · Cited by 60
Morena, F., Argentati, C., Trotta, R., Crispoltoni, L., Stabile, A., Pistilli, A., Di Baldassarre, A., Calafiore, R., Montanucci, P., Basta, G., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081806 · Cited by 57
Photo-oxygenation by a biocompatible catalyst reduces amyloid-β levels in Alzheimer’s disease mice
Ozawa, S., Hori, Y., Shimizu, Y., Taniguchi, A., Suzuki, T., Wang, W., Chiu, Y. W., Koike, R., Yokoshima, S., Fukuyama, T., et al. (2021) · Brain · doi:10.1093/brain/awab058 · Cited by 60
AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy
Ising, C., Gallardo, G., Leyns, C. E. G., Wong, C. H., Jiang, H., Stewart, F., Koscal, L. J., Roh, J., Robinson, G. O., Remolina Serrano, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162125 · Cited by 57
“…safety concern from early immunotherapies targeting Aβ was the development of vascular side effects that led to the discontinuation of an early clinical trial and have continued to be seen with some anti-Aβ antibodies (Senior, 2002; Nicoll et al., 2003; Orgogozo et al., 2003; Sevigny et al., 2016).”
BackgroundMendsaikhan, A., Tooyama, I., Bellier, J.-P., Serrano, G. E., Sue, L. I., Lue, L.-F., Beach, T. G., & Walker, D. G. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0862-8 · Cited by 57
Liu, M., Guo, H. W., Li, Z., Zhang, C., Zhang, X., Cui, Q., & Tian, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.601603 · Cited by 61
“…and Tarenflurbil inhibit enzymes within the Aβ biosynthetic pathway, Tramiprosate and Azeliragon inhibit abnormal aggregation of Aβ, monoclonal antibodies (such as Gantenerumab and Aducanumab) and vaccines (such as ACC-001) against Aβ are also used as immunotherapy (Sevigny et al., 2016; Wu, 2019).”
Discovery of potent inhibitors of α-synuclein aggregation using structure-based iterative learning
Horne, R. I., Andrzejewska, E. A., Alam, P., Brotzakis, Z. F., Srivastava, A., Aubert, A., Nowinska, M., Gregory, R. C., Staats, R., Possenti, A., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01580-x · Cited by 72
Quantitative positron emission tomography in brain research
Heurling, K., Leuzy, A., Jonasson, M., Frick, A., Zimmer, E. R., Nordberg, A. K., & Lubberink, M. (2017) · Brain Research · doi:10.1016/j.brainres.2017.06.022 · Cited by 64
Early affective changes and increased connectivity in preclinical Alzheimer's disease
Fredericks, C. A., Sturm, V. E., Brown, J. A., Hua, A. Y., Bilgel, M., Wong, D. F., Resnick, S. M., & Seeley, W. W. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.06.002 · Cited by 59
Passive antiamyloid immunotherapy for Alzheimer's disease
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., Teixeira, A. L., Forlenza, O. V., & de Souza, L. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000587 · Cited by 56
“However, similarly to bapineuzumab, 22% of aducanumab-treated subjects developed ARIA-E in a dose-dependent and APOEe4-related manner [4].”
BackgroundResultInfluentialGhosh, S., Durgvanshi, S., Agarwal, S., Raghunath, M., & Sinha, J. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200429011823 · Cited by 59
“Even though some additional side effects have been reported, including urinary tract infection, nausea, anxiety, cough and upper respiratory tract infection, it still lacks scientific consensus whether the drug has any involvement with it [4, 9-11].”
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
Herring, W. L., Gould, I. G., Fillit, H., Lindgren, P., Forrestal, F., Thompson, R., & Pemberton-Ross, P. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00273-0 · Cited by 56
Metadata
- Authors
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A.
- Affiliations
- Biogen (United States) (US)
- Light Chain Bioscience (Switzerland) (CH)
- Butler Hospital (US)
- University of Zurich (CH)
- Corresponding author
- Sandrock, Alfred
- ORCID
- Venue
- Nature
- Published
- 2016-08-31
- Volume
- 537
- Issue
- 7618
- Pages
- 50-56
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2510806376
- Cited by
- 3,059
- References
- 42
- Citations by year
- 2026: 186 · 2025: 340 · 2024: 389 · 2023: 332 · 2022: 416 · 2021: 326 · 2020: 263 · 2019: 231 · 2018: 268 · 2017: 252 · 2016: 52
- FWCI
- 214.30
- Type
- journal article
- Language
- en
- Update notices
- addendum (2017-06-22)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- Biogen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid plaques, anti-amyloid monoclonal antibodies, immunotherapy, amyloid hypothesis, transgenic mouse model, prodromal Alzheimer's disease, clinical deterioration, amyloid-related imaging abnormalities, drug safety and tolerability
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Humans, Male, Mice, Transgenic, Middle Aged, Models, Biological, Solubility, Amyloid beta-Peptides, Clinical Trials, Phase III as Topic, Mice, Plaque, Amyloid, Antibodies, Monoclonal, Humanized, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.